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The most common microvascular diabetic complica-
tion, diabetic peripheral polyneuropathy (DPN), affects
type 1 diabetic patients more often and more severely.
In recent decades, it has become increasingly clear that
perpetuating pathogenetic mechanisms, molecular, func-
tional, and structural changes and ultimately the clinical
expression of DPN differ between the two major types of
diabetes. Impaired insulin/C-peptide action has emerged
as a crucial factor to account for the disproportionate
burden affecting type 1 patients. C-peptide was long be-
lieved to be biologically inactive. However, it has now
been shown to have a number of insulin-like glucose-
independent effects. Preclinical studies have demonstrated
dose-dependent effects on Na+,K+-ATPase activity, en-
dothelial nitric oxide synthase (eNOS), and endoneurial
blood ﬂow. Furthermore, it has regulatory effects on neu-
rotrophic factors and molecules pivotal to the integrity of
the nodal and paranodal apparatus and modulatory effects
on apoptotic phenomena affecting the diabetic nervous sys-
tem. In animal studies, C-peptide improves nerve conduc-
tion abnormalities, prevents nodal degenerative changes,
characteristicoftype1DPN,promotesnerveﬁberregenera-
tion,andpreventsapoptosisofcentralandperipheralnerve
cell constituents. Limited clinical trials have conﬁrmed the
beneﬁcial effects of C-peptide on autonomic and somatic
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nerve function in patients with type 1 DPN. Therefore, evi-
dence accumulates that replacement of C-peptide in type 1
diabetespreventsandevenimprovesDPN.Large-scalefood
and drug administration (FDA)-approved clinical trials are
necessary to make this natural substance available to the
globally increasing type 1 diabetic population.
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INTRODUCTION
Diabetic neuropathy is a group of disorders and as such the
most common chronic diabetic complication and affects both
type 1 and type 2 diabetic patients (Greene et al., 1997; Sima,
2003a). Despite decades of intensive clinical and experimental
investigations, diabetic neuropathy remains illusive. Diabetic
neuropathy includes several distinct syndromes, of which sym-
metric, mainly sensory polyneuropathy, often coupled with au-
tonomic polyneuropathy, is the most common and is referred
to as diabetic polyneuropathy (DPN).
The prevalence of DPN varies from 10% within a year of di-
agnosis to 50% in patients with diabetes for 25 years or longer
(Pirart, 1977; Vinik et al., 1992; Sima, 1994), and with an av-
erage prevalence of 30% (Tesfaye et al., 1996). DPN accom-
panying type 1 diabetes occurs more predictably, progresses
more rapidly, resulting in a more severe neuropathy (Dyck
et al., 1999). Close to 100% of type 1 patients eventually de-
velop DPN (Vinik et al., 1992). The underlying causes of DPN
are multiple and involve genetic predispositions and several
interrelated metabolic and molecular abnormalities conse-
quent to hyperglycemia and insulin and C-peptide deﬁcien-
cies (Greene et al., 1992, 1997; Sima, 1996, 2003a, 2003b;
Forst et al., 1998a; Low et al., 1999; Sima and Sugimoto, 1999;
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Sugimoto et al., 2000a). During the last three decades, several
experimental drugs targeting speciﬁc mechanisms have under-
goneclinicaltesting.However,theresultsfromthesetrialshave
been disappointing, which in part may be due to the fact that
therapeutic interventions have occurred too late in the natural
history of DPN or applied compounds have not shown required
potency (Oats and Mylari, 1999; Sima, 2001).
Here we review the key pathogenetic factors involved in
DPN. Differences in underlying mechanisms in type 1 and
type 2 DPNs will be discussed. Clinical and experimental ﬁnd-
ings following C-peptide replacement will be dealt with with
respect to metabolic abnormalities, nerve regeneration, nodal
degeneration, and functional deﬁcits.
THE NATURAL HISTORY OF DPN IN TYPE 1
AND TYPE 2 DIABETES
Data concerning the early development of DPN have almost
exclusivelybeenobtainedfromanimalmodels.Hyperglycemic
streptozotocin (STZ)-induced diabetes in rats or spontaneously
type 1 diabetic BB/Wor-rats show, within weeks of onset, sig-
niﬁcant decreases in motor and sensory nerve conduction ve-
locities(NCVs),associatedwithincreasedactivityofthepolyol
pathway, decreased endoneurial blood ﬂow, and impaired neu-
ral Na+,K+-ATPase and NO activities (Sima and Sugimoto,
1999) (Figure 1). These early functional deﬁcits are reversible
at this “metabolic stage” of DPN. They are associated with
reversible axonal swellings at the node of Ranvier, secondary
to increased intra-axonal Na+ due to the impaired Na+,K+-
ATPase activity (Brismar and Sima, 1981; Sima and Brismar,
1985). Additional pathogenetic components are progressively
emerging, such as oxidative stress and a progressive decline in
the activities of neurotrophic factors, like nerve growth factor
(NGF) and the insulin-like growth factor (IGF) system (Brew-
steretal.,1994;SimaandSugimoto,1999;TomlinsonandFer-
nyhough, 1999). Simultaneously, structural changes develop
consisting of axonal atrophy and axonal dying-back degenera-
tion,whichoccurinalength-dependentmanner(“thestructural
phase”). These changes contribute to the progressively less re-
versible NCV defect (Brismar et al., 1987). Type 1 DPN in
both humans and experimental animal models show additional
structural abnormalities of the nodal and paranodal apparatus
(Brismar et al., 1987; Sima et al., 1988b), changes that do not
occur in type 2 DPN (Sima et al., 1986, 2000) (Figure 2). Ex-
perimentally,thesechangesareassociatedwithlateralizationof
nodal Na+ channel and result in a conduction block of affected
ﬁbers, hence contributing to the progressively less reversible
and more severe NCV deﬁcits in type 1 DPN (Brismar et al.,
1987; Cherian et al., 1996; Sima et al., 2000). Progressive ax-
onaldegeneration,coupledwithimpairedregenerativecapacity,
in the type 1 diabetic BB/Wor rat result in a progressive nerve
FIGURE 1
Pathogenetic mechanisms evolving from hyperglycemia
common to type 1 and type 2 diabetes. Poloyl pathway
activation perturbs Na+,K+-ATPase and NO activities causing
the acute “metabolic” reversible nerve conduction defect.
Several mechanisms contribute to oxidative stress, which in
turn is believed to affect neurotrophic support mechanisms and
possibly apoptosis. These abnormalities lead to axonal
degeneration and loss as well as impaired nerve regeneration,
which constitute the “structural phase” of DPN. During this
phase, nerve conduction defects become increasingly
irreversible. Note nodal/paranodal degeneration (cf., Figure 2)
is not believed to be caused by hyperglycemia per se.
ﬁberloss,whichissigniﬁcantlymilderinitstype2counterpart,
the BBZDR/Wor rat (Sima et al., 2000).
InhumanDPN,thespectrumofsomaticDPNcanbedivided
into reversible and persistent syndromes (Sima et al., 1997b;
Thomas, 1997). The latter is classiﬁed into sensory and mo-
tor syndromes of increasing severity, which reﬂect the natural
history of DPN. Part of the problem in staging and classifying
DPN is that the progression rates of objective functional mea-
surements are not linear and differ between nerves (Laudadio
and Sima, 1996, 1998), reﬂecting the length-dependent axonal
dying-back phenomenon.
Differences exist in the neuropathology of DPN in the two
typesofdiabetes.Thesequenceofnodalandparanodalchanges,
consisting of axoglial dysjunction, paranodal demyelination,
and intercalated internodes, is characteristic of type 1 human
DPN, but does not occur in type 2 DPN (Sima et al., 1988b),
hence showing the same differences as in experimental type 1
and type 2 DPNs. On the other hand, primary segmental de-
myelination tends to be more characteristic of type 2 DPN.TYPE 1 DIABETIC NEUROPATHY AND C-PEPTIDE 67
FIGURE 2
Scheme of pathogenetic mechanisms operable in type 1 DPN. These are initiated by hyperglycemia (cf., Figure 1) and additive
effects of insulin/C-peptide deﬁciencies. C-peptide deﬁciency affects independently Na+,K+-ATPase and NO, causing hypoxia.
Furthermore C-peptide deﬁciency appears to affect neurotrophic mechanisms through gene-regulatory mechanism. This appears
to be more severe than that caused by oxidative stress, which is not effected by C-peptide treatment. Impaired neurotrophism
results in axonal degeneration and loss and impaired regeneration. Insulin/C-peptide deﬁciencies appear to be exclusively
responsible for the progressive nodal and paranodal degenerative changes. Therefore insulin/C-peptide deﬁciencies appears to
several pathogenetic mechanisms also caused by hyperglycemia as well as initiate speciﬁc mechanisms.
These differences are likely to affect nerve function differently
and are likely to account for the clinically more severe DPN in
type 1 diabetic patients (Sima and Cherian, 1997; Dyck et al.,
1999; Sugimoto et al., 2000a). Nevertheless, both type 1 and
type 2 human DPNs shows progressive nerve ﬁber loss (Sima
etal.,1988a).Itisthereforebecomingincreasinglyevidentthat
fundamentaldifferencesdoexistbetweenDPNintype1versus
type 2 diabetes.
ESTABLISHED PATHOGENETIC MECHANISMS
The elucidation of the pathogenetic mechanisms underlying
DPNhaslargelybeenperformedinacutelySTZ-diabeticrat.In
doing so, no distinctions were made as to potential differences
between DPN in the two major types of diabetes, because this
diabetic model is a poor model of the human disorders. Instead
the data from acutely STZ-diabetic rats were extrapolated to
the chronic and diverse human diseases.
Nevertheless,severalmechanismshavebeenrevealed,some
of which show a sustained action from the acute phase of
DPN into the more chronic stage also in the human disorders.
These include the activation of the polyol pathway, oxidative
stress,nonenzymaticglycation,andimpairedneurotrophicsus-
tenance. Because these underlying mechanisms are, in part, fu-
eledbyhyperglycemia(Figure1),itwasandstillisbelievedthat
thebasicandonlyculpritinthedevelopmentofthemicrovascu-
larcomplicationsishyperglycemia,which,henceconveniently,
would explain the development of these complications in both
type 1 and type 2 patients (Dyck and Dyck, 1999; Feldman,
2003).
Polyol Pathway and Associated Abnormalities
The shunting of excessive glucose through the polyol path-
way leads to accumulation of intracellular osmolytes, such as
sorbitol and fructose, at the expense of others, such as myo-
inositol and taurin (Aruoma et al., 1988; Stevens et al., 1993;
Greene et al., 1993). This has several consequences. Depletion
of myo-inositol results in impaired diacylglycerol to maintain
protein kinase C, necessary for activation of Na+,K+-ATPase
(Green et al., 1987; Zhu and Eichberg, 1990; Ishii et al., 1998).
Depletionoftaurinthroughactivationofthepolyolpathwayim-
pairs its action as an endogenous antioxidant and neurotrophic
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1993). Furthermore, activation of the polyol pathway depletes
NADPH, a cofactor of aldose reductase, glutathione reductase,
and endothelial nitric oxide (NO) synthase (eNOS), hence re-
sulting in a decrease in reduced glutathione and impaired NO
formation (Figure 1) (Greene et al., 1993; Stevens et al., 1994).
Theformerresultsindecreaseddefensecapabilitiesagainstox-
idative stress and the latter promotes vascular constriction and
impairednutritivebloodﬂow.Tothesebiochemicalaberrations
should be added that polymorphisms of the initiation site of
the aldose reductase gene in type 1 diabetic patients are associ-
ated with higher frequencies of DPN and diabetic nephropathy
(Heesom et al., 1998; Oates and Mylari, 1999). It is therefore
clear that activation of the polyol pathway has a pathogenetic
role to play and that it promotes other mechanisms indirectly,
suchasoxidativestress,impairednutritivebloodﬂow,andneu-
rotrophic support (Figure 1).
Numerous aldose reductase inhibitor trials were performed
in the 1980s and 1990s with disappointing results. The rea-
sons for this may be several: (1) the underlying rationale was
obtained from data from short-term prevention studies mainly
in STZ-induced diabetic rats; (2) the interventions in human
DPN was too late in its natural history, and (3) many of the
compounds were not potent enough to achieve an efﬁcacious
inhibition of the enzyme. In retrospect, the failures with al-
dose reductase inhibitors underpins the danger of extrapolating
acute animal data to a much more complex chronic but highly
dynamic human disease process (Sima, 2003a, 2003b).
Nonenzymatic Glycation and Oxidative Stress
The glycation process is enhanced in diabetic nerve in hu-
mans and animal models (Vlassara et al., 1981; Araki et al.,
1992; Soulis et al., 1997; Hammes et al., 1999) (Figure 1).
Glycation of neuronal cytoskeletal proteins, such as neuroﬁl-
aments, tubulin, and actin, is likely to contribute to slowing
of axonal transport, atrophy, and degeneration (Cullum et al.,
1991; Ryle et al., 1997) (Figure 1). Glycation of laminin, a key
constituentofSchwanncellbasallamina,whichisimportantin
nerve sprouting, may contribute to impaired nerve ﬁber regen-
eration, characteristic of DPN (Federoff et al., 1993). Several
myelin proteins, such as p-zero (PO), myelin basic protein, and
proteolipid protein, are glycated in diabetes and are recognized
by scavenging macrophages via receptor for advanced glyca-
tionend product (RAGE) (Vlassara et al., 1984, 1985) and may
hence play a contributing role in segmental demyelination.
Oxidative stress facilitates the formation of glycoxida-
tion products such as carboxymethyllsine (CML) and pen-
tosidine (Baynes, 1991). There are several potential sources
of oxidative stress in diabetes, including altered redox sta-
tus (Williamson et al., 1993), dysregulation of glutathione
synthesis (Yoshida et al., 1995), and hypoxia and ischemic
reperfusion injury (McCord, 1985) (Figure 1). Glucose au-
toxidation and glycoxidation, which are catalyzed by trace
amounts of transition metal ions, generate reactive oxy-
gen species (Hunt and Wolff, 1991; Hunt et al., 1988)
(Figure 1). Low-dose transition metal chelators, such as
deferoxamineandtrientine,improvenervebloodﬂowandNCV
in the STZ-diabetic rat (Cameron and Cotter, 1995). Oxidative
stress gives rise to breakdown of endothelial barrier functions
andnuclearfactor(NF)-κB–mediatedgeneinductionsoftissue
factor and endothelin-1, both of which contribute to reduced
vascularbloodﬂow(Bierhausetal.,1997;Wautieretal.,1996).
Tissuelevelsofglycoxidationproductscorrelatewiththesever-
ity of nephropathy, retinopathy, and vasculopathy in diabetic
patients (Sell et al., 1992; Beisswenger et al., 1993; McCance
et al., 1993).
α-Lipoicacidisoneofthemostpowerfulantioxidants.Are-
view of several clinical trials employing α-lipoic acid showed
reduction in neuropathic symptoms and small improvements
of autonomic function (Ziegler et al., 1999). The likelihood
of antioxidant therapy to be successful will probably require
multiple antioxidant compounds targeting the different mecha-
nisms and would include α-lipoic acid, vitamins E and C, and
probably agents targeting the perturbed lipid metabolism such
as γ-linolenic acid (GLA), evening primrose oil/ﬁsh liver oil,
and acetyl-L-carnitine (Cameron and Cotter, 1995; Sima and
Sugimoto, 1999; Sima, 2001).
Perturbed Neurotropism
Evidence indicates that impaired neurotrophic support is
involved in diabetes-related neuronal dysfunctions (Figure 1)
(Brewsteretal.,1994;TomlinsonandFernyhough,1999).NGF
is trophic to small-ﬁber sensory and sympathetic ganglion neu-
rons (Ebendal, 1992). In the STZ-diabetic rat, reduced ex-
pression of NGF mRNA in muscle and skin (Brewster et al.,
1994) and its impaired retrograde axonal transport (Jakobsen
et al., 1981; Hellweg and Hartung, 1990) lead to impaired neu-
rotrophicsupportofNGF-dependentneurons.NGFadministra-
tion prevents the reduction of neuropeptides such as substance
P and calcitonin gene-related peptide in dorsal root ganglion
(DRG) neurons and sciatic nerve in diabetic rats (Apfel et al.,
1994; Diemel et al., 1994). These neuropeptides are conﬁned
to small-ﬁber sensory neurons, mediating nociceptive, or ther-
moreceptive sensation (New and Mudge, 1986).
Neurotrophin-3(NT-3),trophicforsympatheticneuronsand
sensoryneuronsoflarge-diameterﬁbers(Hory-Leeetal.,1993;
Ernfors et al., 1994), is reduced in diabetic muscle. Adminis-
tration of NT-3 ameliorates sensory NCV deﬁcits, but not those
of motor nerves (Tomlinson et al., 1997). Reduced expressionsTYPE 1 DIABETIC NEUROPATHY AND C-PEPTIDE 69
of the high-afﬁnity receptors in respective neurons (Tomlinson
etal.,1997;Fernyhoughetal.,1998)anddecreasedsynthesisof
neurotrophins contribute to nerve dysfunction in DPN. Recent
clinical trials have, however, been inconclusive with respect to
the effect of recombinant human NGF (Apfel, 1999).
IGFs are neurotrophic to sensory, sympathetic, and motor
neurons alike (Ishii, 1995). Reduction in systemic IGF-I levels
and increased IGF-I–binding proteins contribute to impaired
IGF-I activity in type 1 diabetic patients (Crosby et al., 1992).
In the STZ-diabetic rat, the IGF-I mRNA expression is dra-
matically reduced in the liver and in the spinal cord, which
correlates with signiﬁcantly decreased conduction velocities
in both spinal cord and peripheral nerves (Ishii et al., 1994;
Wuarin et al., 1994). Both IGF-I and IGF-II mRNA expres-
sions are signiﬁcantly decreased in sciatic nerve of STZ dia-
betes (Wuarin et al., 1994) and well established in both periph-
eral nerve and the brain in the type 1 BB/Wor rat after 8 weeks
ofdiabetes(Xuetal.,2002;Lietal.,2002a;Piersonetal.,2002,
2003a). Subcutaneous infusion of IGF-I or IGF-II prevents the
progression of hyperalgesia in the STZ-diabetic rat (Zhuang
et al., 1996), and local administration of IGFs protects against
impairments of sensory nerve regeneration (Ishii and Lupien,
1995).
THE ROLES OF INSULIN AND C-PEPTIDE
Lately, it has become clear that hyperglycemia, although
an important etiological factor, is not the sole culprit in the
development of diabetic complications. Increasing attention is
beingpaidtoinsulinand/orC-peptidedeﬁciencies.Bothinsulin
and C-peptide exerts a number of metabolic, neuroprotective,
and antiapoptotic effects (Sima et al., 2001a; Li et al., 2002b,
2003; Pierson et al., 2003b).
Proinsulin C-peptide enhances the effects of insulin
(Johansson et al., 1993; Jensen and Messina, 1999; Grunberger
etal.,2001;Lietal.,2001)andaugmentsphosphorylationofthe
insulin receptor (Li et al., 2001, 2003; Grunberger et al., 2001).
C-peptide signals through the insulin signaling pathway and
stimulates glycogen synthesis and amino acid uptake by itself
andenhancestheseeffectsbyinsulinwithinanarrowconcentra-
tion range (Grunberger et al., 2001; Li et al., 2003; Grunberger
and Sima, 2004) (see below). It was, therefore, suggested that
C-peptideinteractswiththeinsulinreceptor,althoughthebind-
ing of C-peptide to a speciﬁc membrane receptor has also been
suggested (Rigler et al., 1999).
Therefore, the pathophysiological role of proinsulin
C-peptide deﬁciency has received increasing attention, with
particular focus on the potential therapeutic value of C-peptide
replacement in preventing and ameliorating type 1 diabetic
complications.
Metabolic Effects of C-peptide
C-peptide elicits concentration-dependent stimulation of
Na+,K+-ATPase activity in a variety of tissues, including renal
tubular cells, rat sciatic nerve, pancreatic islets, granulation tis-
sue, and red blood cells (Figure 2) (Forst et al., 2000; Wahren
etal.,2000;Zhangetal.,2001;Simaetal.,2001b).Furthersup-
port for C-peptide’s effects on Na+,K+-ATPase is provided by
its effect on rat sciatic nerve Na+,K+-ATPase in type 1 diabetic
BB/Wor rats treated with C-peptide for 8 months, an effect that
is dose dependent (Sima et al., 2001b; Zhang et al., 2001).
This is substantiated by partial correction of the associated
defect in NCV and paranodal swelling, secondary to axonal
Na+ accumulation. Furthermore, in the C-peptide–deﬁcient di-
abeticBB/Worratmodel,theexpressionofbothinsulinreceptor
and IGF-I receptor mRNA and protein in peripheral nerve and
brain tissue are normalized by C-peptide replacement and the
diabetes-induced hippocampal apoptosis is partially prevented
by C-peptide replacement (Li et al., 2003).
Several studies demonstrate an effect of C-peptide on NO
release. It stimulates eNOS with release of NO from bovine
aortic endothelial cells in a concentration-dependent manner,
an effect that is abolished by NOS inhibitors (Figure 2) (Kunt
et al., 2003). This is in keeping with the ﬁnding that C-peptide
inducesincreasedforearmandskinbloodﬂowintype1diabetic
patients, which is blocked by a NOS blocker (Johansson et al.,
1992;Forstetal.,1998a,1998b;ForstandKunt,2004).Itisalso
consistentwiththedemonstrationofaC-peptideconcentration-
dependent dilatation of rat skeletal muscle arterioles in the
presence of insulin (Menegoz et al., 1997). In the BB/Wor rat,
C-peptide prevents the decrease in endoneurial blood ﬂow but
has no effect on oxidative stress (Sima et al., 2003a). The effect
of C-peptide on endoneurial blood ﬂow was also demonstrated
in the STZ-diabetic rat (Cotter et al., 2003).
C-peptidehasnoeffectonthepolyolpathwayactivity;hence
theeffectsonneuralNa+,K+-ATPaseandendothelialNOoccur
independently of this pathway (Figure 2). These data may ac-
count for a different distribution of the Na+,K+-ATPase defect
in type 1 BB/Wor rats (C-peptide deﬁcient) versus the type 2
BBZDR/Wor rat, in which the defect appears to affect mainly
endothelial Na+,K+-ATPase (Sima et al., 2000). Furthermore,
theindependentcorrectionofendothelialNObyC-peptidecer-
tainly contributes to normalization of endoneurial blood ﬂow
without invoking oxidative stress. Taken together, these ben-
eﬁcial metabolic effects are likely to account for the signiﬁ-
cant corrections of the acute nerve conduction defects, despite
the presence of signiﬁcant hyperglycemia. Oxidative stress, it
has been suggested, may provide the ﬁnal common pathway of
theinteractivemetabolicabnormalitiesunderlyingmicrovascu-
lar complications (Feldman, 2003; Brownlee, 2001). However,
the data cited above appear to challenge this concept, because70 A. A. F. SIMA ET AL.
C-peptide administration corrects several metabolic abnormal-
ities,whichsupposedlycontributetooxidativestress,aswellas
nervefunction,althoughitdoesnotaffectoxidativestressperse.
The Effect of C-peptide on Nerve Function
As would be expected from the corrective effects on neu-
ral Na+,K+ -ATPase, endothelial NO, and endoneurial blood
ﬂow, C-peptide signiﬁcantly prevents both motor and sensory
NCVs as well as thermal hyperalgesia, a function of C-ﬁbers
(Simaetal.,2001b,2003b;Stevensetal.,2003).However,these
effects are not complete but are associated with sometimes sig-
niﬁcant residual functional defects, which are most likely ac-
counted for by additive hyperglycemic effects on underlying
metabolic abnormalities (Figure 3). Apart from the acute ef-
fects on nerve functions in type 1 diabetic BB/Wor rats, sus-
tainedC-peptidereplacementpreventssigniﬁcantlythechronic
functional abnormalities (Sima et al., 2001b). These effects are
associatedwithpreventiveeffectsonemergingstructuralabnor-
malities,particularlyaxonaldegenerationandlossandprobably
FIGURE 3
Nerve conduction velocities in age-matched control rats,
8-month type 1 BB/Wor and type 2 BBZDR/Wor-rats. Note a
signiﬁcantly (P <. 001) nerve conduction defect in type 2 rats.
Prevention with C-peptide (0 to 8 months) resulted in a
signiﬁcant (P <. 001) amelioration of the conduction defect.
Intervention with C-peptide (5 to 8 months) resulted in a
signiﬁcant (P <. 006) improvement of nerve conduction. Note
the nerve conductions in C-peptide–replaced animals were
similar to those in type 2 diabetic rats, suggesting a
hyperglycemic component and an insulin/C-peptide
deﬁciency–related component. ∗P <. 001 versus control rats;
†P <. 001 versus BB/Wor rats (Data from Sima et al., 2001).
most importantly the preventive effects on the speciﬁc type 1
degenerativechangesaffectingthenodalandparanodalappara-
tus (Sima et al., 2001b) (Figure 2) (see below). From a clinical
viewpoint, a more encouraging ﬁnding is the therapeutic effect
of C-peptide replacement on established experimental DPN,
with signiﬁcant functional improvements. These are associated
and correlated with reparative effects on underlying structural
abnormalities (Sima et al., 2001b) (see below). These ﬁndings
suggest that insulinomimetic C-peptide has a ubiquitous effect
on both myelinated and unmyelinated ﬁber populations and
parallel a recent randomized, double-blind, placebo-controlled
study, in which Ekberg and colleagues (2003) demonstrated
that replacement with C-peptide (600 nmol/day) resulted in
signiﬁcant improvements in nerve function. C-peptide–treated
patients showed signiﬁcant (80%) improvement in sural NCV
and vibration perception over a 3-month treatment period, as
compared to patients treated with insulin alone. Earlier studies
bythesamegroup(Ekbergetal.,2003)alsodemonstratedbene-
ﬁcialeffectsoncardiacautonomicfunctionaswellasimproved
temperature threshold discrimination after C-peptide replace-
ment of type 1 diabetic patients (Johansson et al., 2000). None
of these effects were demonstrated in patients who received
insulin therapy alone.
Effect of C-peptide on Axonal Degeneration
and Loss
Long-term preventive studies in the spontaneously type 1
diabetic BB/Wor rat have demonstrated signiﬁcant preventive
effects on axonal atrophy, degeneration, and loss of myelinated
ﬁbers (Sima et al., 2001b, 2002, 2003b) (Figures 4 and 5).
Similarly,C-peptidepreventsatrophyandlossofunmyelinated
ﬁbersinthesuralnerveofthesamemodel(SimaandMurakawa,
unpublished data). However, these effects on myelinated and
unmyelinated ﬁber pathology was not always complete but left
asigniﬁcantlymilderresidualDPN,whichwasnotsigniﬁcantly
differentfromthemarkedlymilderneuropathycausedbyhyper-
glycemicandhyperinsulinemictype2diabetesinBBZDR/Wor
rats (Sima et al., 2001b). Corresponding to the interventional
effects on nerve function described above, intervention with
C-peptidefrom5to8monthsofdiabetesresultedinan80%im-
provement in axonal degenerative changes and signiﬁcant pro-
tections against myelinated and unmyelinated ﬁber loss (Sima
et al., 2001b; Sima and Murakawa, unpublished data). Both
the preventive and therapeutic effects of C-peptide are likely
to be mediated by the corrective effects on the expression of
neurotrophic factors transcending to normalization of the ex-
pression of key neuroskeletal proteins such as β-tubulins and
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FIGURE 4
Frequency of myelinated ﬁbers of the sural nerve showing
axonal degeneration in the same groups of animals as in
Figure 3. BB/Wor rats showed a 10-fold increase in axonal
degeneration (P <. 001) and a 4-fold (P <. 001) increase in
type 1 BBZDR/Wor rats. Both C-peptide prevention and
intervention reduced the frequencies of axonal degeneration to
approximately 2-fold of control rats, which were signiﬁcant
compared to untreated BB/Wor rats (P <. 001). ∗P <. 001
versus control rats; †P <. 001 versus untreated BB/Wor rats.
Effect of C-peptide on Neurotrophism
Evidence indicates that impaired neurotrophic support
plays a role in DPN (Brewster et al., 1994; Tomlinson and
Fernyhough, 1999). NGF is selectively trophic to small ﬁber
sensory and sympathetic ganglia (Ebendal, 1992). Reduced ex-
pression of NGF and its impaired retrograde axonal transport
lead to impaired trophic support of NGF-dependent neurons
(Jakobsen et al., 1981; Hellweg and Harting, 1990). Further-
more, impairments in NGF receptors are likely to contribute
to reduced responses. The low afﬁnity p75 receptor undergoes
increased turnover in diabetic nerve (Hruska et al., 1993). Ex-
pressionofthehigh-afﬁnityTrkAreceptorismarkedlyreduced
in DRG of BB/Wor rats but not in type 2 BBZDR/Wor rats
(Pierson et al., 2002). Replenishment of C-peptide in the type 1
BB/Wor rat totally prevents the defect in TrkA receptor expres-
sion (Pierson et al., 2003b).
IGFshaveneurotrophicactionsonsensory,sympathetic,and
motorneurons(Ishii,1995).IntheSTZ-diabeticratandBB/Wor
rat, IGF-I mRNA expression is dramatically reduced in periph-
eral nerve, DRG, and spinal cord (Ishii et al., 1994; Wuarin
et al., 1994; Xu et al., 2002). Interestingly, in the BB/Wor rat,
the IGF-I receptor is up-regulated in peripheral nerve and DRG
FIGURE 5
Frequencies of axoglial dysjunction, the hallmark of type 1
DPN, assessed by ultrastructural morphometry. Animal groups
are the same as in Figure 3. Axoglial dysjunction was
increased 3.5-fold (P <. 001) compared to control rats,
whereas no signiﬁcant axoglial dysjunction occurred in type 2
BBZDR/Wor rats. C-peptide prevention and intervention
resulted in signiﬁcant (P <. 001) decreases in the frequencies
of axoglial dysjunction, although in the intervention group (5
to 8 months), a residual (P <. 05) defect remained compared
to control rats. Data are obtained from Sima et al., 2001.
∗P <. 001 versus control rats; †P <. 001 vs nontreated
BB/Wor rats;
§P <. 05 versus control rats.
but down-regulated in the brain (Pierson et al., 2003a, 2003b;
Xu et al., 2002; Li et al., 2002a). These abnormalities are sig-
niﬁcantly milder in the spontaneously type 2 diabetic BB/Z rat
andunalteredinthefa/farat(Zhuangetal.,1997;Piersonetal.,
2002, 2003a). In the STZ-diabetic rat, subcutaneous infusion
of IGF-I or IGF-II prevents the progression of hyperalgesia
(Zhuang et al., 1996) and local administration of IGFs pro-
tects against impairments in sensory nerve regeneration (Ishii
and Lupien, 1995). The abnormalities in IGF-I and IGF-I re-
ceptor expression in peripheral nerve, DRG, and brain in the
type 1 BB/Wor rat are normalized by C-peptide replacement
(Pierson et al., 2003b; Li et al., 2002a), believed to be related to
a phosphoinositol 3-kinase (PI3K)-mediated effect on NF-κB
(Li et al., 2003).
Effect of C-peptide on Nerve Regeneration
Progressive nerve ﬁber loss in DPN (Thomas and Eliasson,
1984; Greene et al., 1997) is in part due to impaired nerve72 A. A. F. SIMA ET AL.
ﬁber regeneration (Sima et al., 1988a). Nerve regeneration is
a tightly regulated spatiotemporal sequence of events involv-
ing immediate early gene responses such as IGF-I → c-fos →
NGF (Hengerer et al., 1990; Xu and Sima, 2001), activation of
interleukins and cytokines, macrophage recruitment, wallerian
degeneration,inductionofcytoskeletalproteinsynthesis,andﬁ-
nally axonal sprouting, elongation, and maturation (Ide, 1996).
Several of these components are perturbed in type 1 diabetes,
such as altered immediate early gene responses (Xu and Sima,
2001; Pierson et al., 2002, 2003a), delayed wallerian degenera-
tion, delayed onset and rate of regeneration, and impaired mat-
urationofregeneratedﬁbers(Kamijoetal.,1996).Cytoskeletal
proteins synthesized in DRG are affected by DPN. Both per-
turbed synthesis and slowed transport of neuroﬁlaments have
been described. The importance of neuroﬁlaments in deter-
mining axonal caliber and, thereby, conduction velocity has
been demonstrated (Yagihashi et al., 1990; Ide, 1996; Kamijo
et al., 1996; Sima, 1999). Tubulins are major components of
microtubules. Together with actin ﬁlaments, microtubules play
important roles in directional outgrowth of neurites, such as
growth cone advance and polarity (Mitchison and Kirschner,
1988). Alterations in microtubule proteins affecting the assem-
bly and stability of microtubules are therefore likely to mod-
ify axonal function and to inﬂuence neuronal remodeling and
regeneration.
Signiﬁcantly delayed and suppressed immediate early gene
responses,impairedmacrophagerecruitment,andwalleriande-
generation have been demonstrated in the type 1 BB/Wor rat
(Kamijo et al., 1996; Sima et al., 1997a; Xu and Sima, 2001;
Xu et al., 2002; Pierson et al., 2002, 2003b). These abnormali-
ties are associated with impaired up-regulation of tubulin and a
lack of normal down-regulation of neuroﬁlament expression in
DRGsprecededbyadown-regulationofIGF-I,trkA,andp75in
DRGganglioncells(Xuetal.,2002).Thisledustosuggestthat
tubulin expression exerts a negative feedback on neuroﬁlament
expression to facilitate the early transport of tubulins to initi-
ate the growth cone extension (Xu et al., 2002). The sequence
of abnormalities ultimately resulted in impaired axonal caliber
growth and extension. Parallel studies in the isohyperglycemic
and hyperinsulinemic type 2 BB/Z rat failed to demonstrate
any major abnormalities in this sequence of events and showed
more robust nerve ﬁber regeneration (Pierson et al., 2003a).
C-peptide–replaced type 1 rats exhibited mild changes com-
paredtononreplacedanimals(Piersonetal.,2003b).C-peptide
normalized the immediate early gene response and the expres-
sion of neurotrophic factors and their receptors, tubulin, and
neuroﬁlaments in DRG neurons, resulting in normalization of
axonalcalibergrowthandimprovementoftheelongationofre-
generating ﬁbers. These ﬁndings are likely to contribute to the
preventionofnerveﬁberlossintype1BB/Worratsreplenished
with C-peptide (Sima et al., 2001b) and suggest that impaired
nerve regeneration is a more prominent phenomenon in type 1
DPN and may contribute to the more severe clinical expression
of DPN in this type of diabetes. Impaired nerve regeneration
appears to be mainly the result of impaired insulin/C-peptide
action rather than hyperglycemia.
Effect of C-peptide on Nodal
and Paranodal Changes
The high-afﬁnity insulin receptor in peripheral nerve is lo-
calized to the nodal axolemma and to paranodal tight junc-
tions (Sugimoto et al., 2000b). The protein expression of the
insulin receptor is compensatorily overexpressed in peripheral
nerve of BB/Wor rats, which is corrected by C-peptide, and un-
derexpressed in the hyperinsulinemic type 2 BBZDR/Wor rat
(Pierson et al., 2002, 2003b).
The molecular components of the node of Ranvier and the
paranodal apparatus and their interactive regulation are com-
plex and not fully understood. Voltage-gated Na+ channels are
locatedtothenodalapparatusandareresponsibleforactionpo-
tentialinitiationandconduction.Theyconsistofapore-forming
α-subunit and two auxiliary subunits: β1 and β2. Cytoskeletal
interactions with spectrin, actin, and contactin (Scherer, 1996;
Lambert et al., 1997) occur through ankyrinG and appear to be
critical to Na+ channel and Na+,K+-ATPase enrichment at the
node (Muller-Husman et al., 1993; Malhotra et al., 2000; Isom,
2002).Theβ1 subunit,butnotthatofβ2,interactswithreceptor
tyrosine phosphatase β (RTPTβ), which in turn acts as a lig-
and for the neuroreceptor contactin (Peles et al., 1995; Ratcliff
et al., 2000). RTPTβ is part of the insulin and NGF signaling
pathways.
At the paranode, caspr makes up the tight junctions. These
are also associated with spectrin, actin, and contactin, which,
via β1 Na+ channel subunit and RTPTβ, interact with caspr
(Einheberetal.,1997;Menegozetal.,1997;Pelesetal.,1997).
SH3 domains of caspr appear to be responsible for the protein-
protein interaction and bind with p85, the regulatory subunit
of PI3K. Type 1 diabetic BB/W rat show a down-regulation of
several key nodal and paranodal molecules, such as contactin,
β1 Na+ channelsubunit,caspr,andRTPTβ (Simaetal.,2003a).
This does not occur in the type 2 BB/Z rat and is prevented by
replenishing C-peptide in type 1 diabetic rats. Interestingly the
expression of the pore-forming α Na+ channel subunit is not
alteredineithertype1ortype2BBrats.Post-translationalmod-
iﬁcationsofparanodalandnodalmoleculesexaminedinhuman
neuroblastoma cells SH-SY5Y show that maximal p85 binding
to caspr and serin phosphorylation of ankyrinG occur only in
thepresenceofbothinsulinandC-peptide.Thesemodiﬁcations
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the node, respectively (Sima et al., 2003b). Hence these data
indicate that insulin and C-peptide deﬁciencies perturb the ex-
pression of crucial nodal and paranodal molecules and that
impaired insulin action is likely to interfere with their assem-
bly, thereby leading to the progressive disruption of the paran-
odal apparatus, which characterizes type 1 DPN in humans and
rodents alike. This is further supported by the intimate colo-
calization of the insulin-receptor with paranodal tight junctions
and the nodal membrane (Sugimoto et al., 2000b). These data
thereforeindicatethatinsulin/C-peptidedeﬁcienciesaremainly
responsible for the progressive nodal and paranodal degenera-
tive changes, which set the more severe type 1 DPN apart from
its type 2 counterpart in both human and experimental rodent
models.
CONCLUDING THOUGHTS
By utilizing animal models that closely mimic the two ma-
jor types of human diabetes, it is becoming increasingly ev-
ident that fundamental differences exist with respect to un-
derlying pathogenetic mechanisms of the DPN occurring in
type 1 versus type 2 diabetes. The most evident difference be-
tween the two types of diabetes is the presence and absence
of insulin/C-peptide action. As reviewed in this article, the in-
sulinomimeticeffectsofC-peptideiscapableofpreventingand
in some instances improving established metabolic and func-
tional and structural abnormalities, ameliorating aberrations in
neurotrophic support and dysregulation of a series of interac-
tive nodal and paranodal molecules. This is not to say that hy-
perglycemia is not an important player in the development of
DPN, but we would argue that impaired insulin/C-peptide ac-
tions appears to be at least an equally important offender in the
evolution of type 1 DPN. Preclinical data and small clinical tri-
als clearly indicate that substantial beneﬁts can be gained from
replacement of not only insulin (for blood glucose control), but
alsoC-peptideincontrollingtype1diabeticDPNandprobably
other type 1 microvascular complications.
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